STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GSK CEO Luke Miels, six months into the role, unveiled a three-year plan to generate £1.9 billion (~$2.5 billion) in annual savings by 2029, much of which the company says will be reinvested into its late-stage pipeline
- GSK now plans to launch at least 20 Phase 3 trials this year, up from the 10 it had disclosed at the start of 2026 — effectively doubling its late-stage clinical activity
- Miels said GSK is 'step-by-step building a set of potential best-in-class products' across core therapy areas, including newer targets like oncology and liver disease alongside longstanding franchises in vaccines and HIV
- Miels declined to specify how many jobs would be eliminated under the savings drive, leaving the employment impact of the £1.9 billion target undisclosed
Why it matters: The £1.9 billion savings target by 2029 frees up capital for GSK to roughly double its Phase 3 trial count this year, a high-stakes bet that a deeper late-stage pipeline will offset cost reductions — but the undisclosed headcount leaves the human cost of the restructuring unquantified for investors and employees.
